Kolistimetatnatrium Noridem

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Noridem, is a Polymyxin antibiotic presented as an inhalation solution for inhalation use. It is employed to treat chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis and related chronic respiratory conditions. The product complies with EU pharmaceutical standards and is formulated for nebulised delivery to the lower airways.

GNH USA supplies Kolistimetatnatrium Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kolistimetatnatrium Noridem is a Polymyxin antibiotic used to manage chronic Pseudomonas aeruginosa infections in the respiratory tract.

- Cystic fibrosis: reduces bacterial load and improves lung function in patients with chronic Pseudomonas infection. - Non‑cystic fibrosis bronchiectasis: helps control persistent Pseudomonas colonisation and decreases exacerbation frequency. - Chronic Pseudomonas aeruginosa lung infection: supports airway clearance and reduces the risk of acute worsening.

Adverse reactions may occur with inhaled colistimethate sodium. Monitoring for respiratory and systemic effects is recommended.

Common Side Effects: - Cough: mild to moderate irritation of the airways. - Bronchospasm: transient narrowing of the bronchial passages. - Throat irritation: discomfort or soreness in the throat. - Nausea: occasional gastrointestinal upset. - Dysgeusia: altered taste sensation. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Respiratory distress: severe bronchospasm or hypoxia. - Allergic reaction: rash, urticaria, or anaphylaxis. - Nephrotoxicity: impaired kidney function, especially with systemic absorption. - Neurotoxicity: paresthesia, dizziness, or seizures. - Hemoptysis: coughing up blood. - Elevated liver enzymes: signs of hepatic involvement.

Use of inhaled colistimethate sodium requires careful patient assessment and monitoring.

- Renal function: assess baseline kidney status and monitor periodically. - Hepatic function: evaluate liver enzymes before initiating therapy. - Respiratory status: ensure patient can tolerate nebulised administration; monitor for bronchospasm. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk. - Concomitant nephrotoxic drugs: avoid or adjust dosing when used together. - Store below 25°C: keep in original container, protect from light and moisture.

Colistimethate sodium may interact with other medications, influencing safety or efficacy.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., aminoglycosides, vancomycin): combined use may increase risk of kidney injury. - Neuromuscular blockers (e.g., curare): may potentiate neuromuscular weakness.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance renal effects; monitor electrolytes. - Other inhaled antibiotics: assess cumulative respiratory irritation. - CYP450 substrates: colistin is not a major CYP inhibitor, but monitor for unexpected changes.